-
1
-
-
0029074925
-
Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications
-
Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin. Pharmacokinet. 1995; 29: 142-53.
-
(1995)
Clin. Pharmacokinet.
, vol.29
, pp. 142-153
-
-
Salvà, P.1
Costa, J.2
-
2
-
-
0032986686
-
Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations
-
Von Moltke LL, Greenblatt DJ, Granda BW et al. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br. J. Clin. Pharmacol. 1999; 48: 89-97.
-
(1999)
Br. J. Clin. Pharmacol.
, vol.48
, pp. 89-97
-
-
Von Moltke, L.L.1
Greenblatt, D.J.2
Granda, B.W.3
-
3
-
-
12944331138
-
Zolpidem. A review of its use in the management of Insomnia
-
Harrison TS, Keating GM. Zolpidem. A review of its use in the management of Insomnia. CNS Drugs 2005; 19: 65-89.
-
(2005)
CNS Drugs
, vol.19
, pp. 65-89
-
-
Harrison, T.S.1
Keating, G.M.2
-
4
-
-
67349106390
-
Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem
-
Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clin. Pharmacol. Ther. 2009; 85: 644-50.
-
(2009)
Clin. Pharmacol. Ther.
, vol.85
, pp. 644-650
-
-
Farkas, D.1
Volak, L.P.2
Harmatz, J.S.3
von Moltke, L.L.4
Court, M.H.5
Greenblatt, D.J.6
-
5
-
-
84855162939
-
Sanofi-Aventis US LLC
-
Prescribing information. (Online); Available from: (accessed 18 August)
-
Sanofi-Aventis US LLC. Ambiem (zolpidem tartrat) tablets CIV: Prescribing information. (Online); Available from: (accessed 18 August 2011).
-
(2011)
Ambiem (zolpidem tartrat) tablets CIV:
-
-
-
6
-
-
33845408447
-
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects
-
Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br. J. Clin. Pharmacol. 2006; 63: 116-20.
-
(2006)
Br. J. Clin. Pharmacol.
, vol.63
, pp. 116-120
-
-
Saari, T.I.1
Laine, K.2
Leino, K.3
Valtonen, M.4
Neuvonen, P.J.5
Olkkola, K.T.6
-
7
-
-
34250630391
-
Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine
-
Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ. Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine. Clin. Pharmacol. Ther. 2007; 82: 54-62.
-
(2007)
Clin. Pharmacol. Ther.
, vol.82
, pp. 54-62
-
-
Cysneiros, R.M.1
Farkas, D.2
Harmatz, J.S.3
von Moltke, L.L.4
Greenblatt, D.J.5
-
9
-
-
0031025875
-
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism
-
Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin. Pharmacokinet. 1997; 32(Suppl. 1): 1-21.
-
(1997)
Clin. Pharmacokinet.
, vol.32
, Issue.SUPPL. 1
, pp. 1-21
-
-
Preskorn, S.H.1
-
10
-
-
48549093980
-
Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update
-
Spina E, Santoro V, D'Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: An update. Clin. Ther. 2008; 30: 1206-27.
-
(2008)
Clin. Ther.
, vol.30
, pp. 1206-1227
-
-
Spina, E.1
Santoro, V.2
D'Arrigo, C.3
-
11
-
-
0029160813
-
Overview of the pharmacokinetics of fluvoxamine
-
van Harten J. Overview of the pharmacokinetics of fluvoxamine. Clin. Pharmacokinet. 1995; 29(Suppl. 1): 1-9.
-
(1995)
Clin. Pharmacokinet.
, vol.29
, Issue.SUPPL. 1
, pp. 1-9
-
-
van Harten, J.1
-
12
-
-
0031979755
-
Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications
-
Caccia S. Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet. 1998; 34: 281-302.
-
(1998)
Clin. Pharmacokinet.
, vol.34
, pp. 281-302
-
-
Caccia, S.1
-
13
-
-
0023615056
-
A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability
-
Schuirmann DJ. A comparison of the 2 one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 1987; 15: 657-80.
-
(1987)
J. Pharmacokinet. Biopharm.
, vol.15
, pp. 657-680
-
-
Schuirmann, D.J.1
-
14
-
-
84855163759
-
U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
-
Bioavailability and bioequivalence studies for orally administered drug products-general considerations. July 2002. (online) Available from: (accessed 18 August)
-
U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products-general considerations. July 2002. (online) Available from: (accessed 18 August 2011).
-
(2011)
Guidance for industry
-
-
-
15
-
-
84855163762
-
The European Agency for the Evaluation of Medicinal Products, Committee for medicinal products for human use
-
London, January 2010. (online) Available from: (accessed 18 August).
-
The European Agency for the Evaluation of Medicinal Products, Committee for medicinal products for human use. Guideline on the investigation of bioequivalence. London, January 2010. (online) Available from: (accessed 18 August 2011).
-
(2011)
Guideline on the investigation of bioequivalence
-
-
-
16
-
-
84855163759
-
U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research
-
In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. November 1999. (online). Available from: (accessed 18 August)
-
U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. November 1999. (online). Available from: (accessed 18 August 2011).
-
(2011)
Guidance for industry
-
-
-
17
-
-
84855162938
-
-
U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Draft guidance. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. September 2006. (online) Available from: (accessed 18 August 2011)
-
U. S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry. Draft guidance. In vivo drug metabolism/drug interaction studies - study design, data analysis, and recommendations for dosing and labeling. September 2006. (online) Available from: (accessed 18 August 2011).
-
-
-
-
19
-
-
73849111326
-
Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum
-
Neve EPA, Ingelman-Sundberg M. Cytochrome P450 proteins: Retention and distribution from the endoplasmic reticulum. Curr. Opin. Drug Discov. Devel. 2010; 13: 78-85.
-
(2010)
Curr. Opin. Drug Discov. Devel.
, vol.13
, pp. 78-85
-
-
Neve, E.P.A.1
Ingelman-Sundberg, M.2
-
20
-
-
0033952872
-
Central nervous system side effects associated with zolpidem treatment
-
Toner LC, Tsambiras BM, Catalano G, Catalano MC, Cooper DS. Central nervous system side effects associated with zolpidem treatment. Clin. Neuropharmacol. 2000; 23: 54-8.
-
(2000)
Clin. Neuropharmacol.
, vol.23
, pp. 54-58
-
-
Toner, L.C.1
Tsambiras, B.M.2
Catalano, G.3
Catalano, M.C.4
Cooper, D.S.5
-
21
-
-
79251482736
-
Adverse reactions to zolpidem: Case reports and a review of the literature
-
PCC.09r00849. Available from, accessed 21 September 2011)
-
Inagaki T, Miyaoka T, Tsuji S, Inami Y, Nishida A, Horiguchi J. Adverse reactions to zolpidem: Case reports and a review of the literature. Prim. Care Companion J. Clin. Psychiatry. 2010; 12: PCC.09r00849. Available from:, (accessed 21 September 2011).
-
(2010)
Prim. Care Companion J. Clin. Psychiatry
, vol.12
-
-
Inagaki, T.1
Miyaoka, T.2
Tsuji, S.3
Inami, Y.4
Nishida, A.5
Horiguchi, J.6
-
22
-
-
33750293947
-
Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: A possible interaction
-
Kito S, Koga Y. Visual hallucinations and amnesia associated with zolpidem triggered by fluvoxamine: A possible interaction. Int. Psychogeriatr. 2006; 18: 749-51.
-
(2006)
Int. Psychogeriatr.
, vol.18
, pp. 749-751
-
-
Kito, S.1
Koga, Y.2
|